Table 3.
Cardiac magnetic resonance data of patients before and following one-year tocotrienol treatment (mean ± std dev) and relative statistical significance (Student’s t test).
| FE Vsx(56–79%) | Vol TD Vsx(47–92 mL/m2) | Vol TS Vsx(14–39 mL/m2) | SV Vsx(37–62 mL/m2) | Sp Td SIV(5–8 mm) | Sp Td PP(5–7 mm) | M Vsx(70–113 g/m2) | M Lenha(g/m2) | % M Lenha | |
|---|---|---|---|---|---|---|---|---|---|
| FRDA patients at time 0 | 65.56 ± 12.18 | 62.20 ± 16.08 | 22.60 ± 13.58 | 39.60 ± 4.93 | 12.0 ± 3.67 | 10.0 ± 3.46 | 65.86 ± 17.19 | 12.36 ± 9.50 | 14.78 ± 8.05 |
| FRDA patients post-1 year treatment | 61.66 ± 10.49 | 57.26 ± 29.93 | 29.02 ± 18.50 | 43.04 ± 13.90 | 12.20 ± 3.96 | 8.80 ± 2.17 | 60.54 ± 12.78 | 7.50 ± 5.82 | 13.62 ± 7.58 |
| P | 0.090 | 0.677 | 0.137 | 0.619 | 0.883 | 0.493 | 0.311 | 0.497 | 0.852 |
Note: Values in brackets are the normal range for the healthy subjects. Normal values for Lenh are not reported.
aData relating only to four of the five patients.
FE: ejection fraction, Vsx left ventricle; VolTd: end-diastolic volume; VolTs: end-systolic volume; SV: stroke volume; Sp: thickness; SIV: interventricular septum; PP: posterior wall; M: mass; Lenh: late enhancement (delayed wash out of intramyocardial gadolinium); % M: percentage of myocardial mass with positivity to late enhancement.